The World Health Organization (WHO) recently announced that the monkeypox outbreak constitutes a “Public Health Emergency of International Concern.” This is the second time since July 2022 that the WHO has issued the highest level of alert for the monkeypox outbreak, drawing significant international attention. According to WHO data, more than 15,600 cases of monkeypox have been reported this year, surpassing the total number of cases last year, with 537 deaths. Since July 2024, over 100 laboratory-confirmed cases of clade 1b have been reported in four neighboring countries of the Democratic Republic of the Congo: Burundi, Kenya, Rwanda, and Uganda. Currently, the monkeypox virus has erupted in non-endemic countries and regions, making precise diagnosis and specific prevention/treatment of the monkeypox virus an urgent need. We provide solutions for recombinant antigens, antibodies, enzymes, and reagents for monkeypox virus, used in disease diagnosis and vaccine drug development.